Cargando…
Anti–PD-L1 Treatment Induced Central Diabetes Insipidus
CONTEXT: Immune checkpoint inhibitors, including anti–programmed cell death protein 1 (PD-1), anti–programmed cell death protein ligand 1 (PD-L1), and anti–cytotoxic T-lymphocyte antigen 4 (anti-CTLA4) monoclonal antibodies, have been widely used in cancer treatment. They are known to cause immune-r...
Autores principales: | Zhao, Chen, Tella, Sri Harsha, Del Rivero, Jaydira, Kommalapati, Anuhya, Ebenuwa, Ifechukwude, Gulley, James, Strauss, Julius, Brownell, Isaac |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5800826/ https://www.ncbi.nlm.nih.gov/pubmed/29220526 http://dx.doi.org/10.1210/jc.2017-01905 |
Ejemplares similares
-
Thyrotoxic Periodic Paralysis: An Underdiagnosed and Under-recognized Condition
por: Tella, Sri Harsha, et al.
Publicado: (2015) -
Profile of Abaloparatide and Its Potential in the Treatment of Postmenopausal Osteoporosis
por: Tella, Sri Harsha, et al.
Publicado: (2017) -
Evaluating the Safety and Efficacy of Nivolumab in Patients with Advanced Hepatocellular Carcinoma: Evidence to Date
por: Tella, Sri Harsha, et al.
Publicado: (2019) -
First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination
por: Tella, Sri Harsha, et al.
Publicado: (2022) -
Potential Role of Metabolic Intervention in the Management of Advanced Differentiated Thyroid Cancer
por: Tella, Sri Harsha, et al.
Publicado: (2017)